Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Godai, Ten i ^a   Suda, Tetsuji ^a   Sugano, Nobuhiro ^a   Tsuchida, Kazuhito ^a   Shiozawa, Manabu ^a   Sekiguchi, Hironobu ^a   Sekiyama, Akiko ^a   Yoshihara, Mitsuyo ^a   Matsukuma, Shoichi ^a   Sakuma, Yuji ^a   Tsuchiya, Eiju ^a   Kameda, Yoichi ^a   Akaike, Makoto ^a   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PROLINE; PROTEIN P53; PROTEIN P72; UFT; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CODON; COLORECTAL CANCER; DNA POLYMORPHISM; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME; SURVIVAL TIME; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; AGED; ALLELE; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

AGED; ALLELES; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CODON; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROLINE; TUMOR MARKERS, BIOLOGICAL;

EID: 73149112621     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-420     Document Type: Article

References (40)

1. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004, 95:7-11. 10.1111/j.1349-7006.2004.tb03163.x, 14720320.
2. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994, 91:5320-5324. 10.1073/pnas.91.12.5320, 43986, 8202487.
3. Naumovski L, Cleary ML. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996, 16:3884-3892. 231385, 8668206.
4. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389:300-305. 10.1038/38525, 9305847.
5. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584. 10.1126/science.7521539, 7521539.
6. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000, 404:42-49. 10.1038/35003506, 10716435.
7. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878.
8. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998, 16:3269-3277. 10.1038/sj.onc.1201867, 9681825.
9. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485. 10.1038/sj.onc.1202314, 9927204.
10. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009, 9:95-107. 10.1038/nrc2584, 19165225.
11. Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 2009, 16:1-12. 10.1038/cgt.2008.69, 18802452.
12. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393:229-233. 10.1038/30400, 9607760.
13. Irarrázabal CE, Rojas C, Aracena R, Márquez C, Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 2003, 144:69-76. 10.1016/S0378-4274(02)00336-3, 12919725.
14. Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, Chen CJ, Hsieh CY, Wu MT. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000, 89:458-464. 10.1002/1097-0215(20000920)89:5<458::AID-IJC10 7>3.0.CO;2-R, 11008209.
15. Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996, 17:1313-1316. 10.1093/carcin/17.6.1313, 8681448.
16. Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 2003, 189:77-83. 10.1016/S0304-3835(02)00518-9, 12445680.
17. Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006, 12:1426-1429.
18. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007, 37:385-390. 10.1093/jjco/hym034, 17599946.
19. Själander A, Birgander R, Athlin L, Stenling R, Rutegård J, Beckman L, Beckman G. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995, 16:1461-1464. 10.1093/carcin/16.7.1461, 7614678.
20. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004, 6:529-535. 10.1593/neo.04178, 1531656, 15548361.
21. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000, 25:47-54. 10.1038/75586, 10802655.
22. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001, 21:1874-1887. 10.1128/MCB.21.5.1874-1887.2001, 86759, 11238924.
23. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 2007, 26:2220-2225. 10.1038/sj.onc.1210311, 17401431.
24. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402. 10.1016/S1535-6108(03)00079-5, 12726864.
25. McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'nions J, Young AR, Surentheran T, Breuer J, Millard TP, Lewis CM, Leigh IM. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002, 119:84-90. 10.1046/j.1523-1747.2002.01655.x, 12164929.
26. Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002, 11:1684-1688.
27. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005, 26:1770-1773. 10.1093/carcin/bgi125, 15905205.
28. Hamilton S, Aaltonen L, . Eds WHO classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. 2000, Lyon, IARC press.
29. Sobin LH, Wittekind C, . Eds UICC, TNM Classification of Malignant Tumors, 6th ed. 2002, New York: John Wiley & Sons.
30. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumors arising in Arg/Pro germline heterozygotes. Br J Cancer 2002, 87:1013-1018. 10.1038/sj.bjc.6600595, 2364333, 12434294.
31. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993, 21:3623-3629. 10.1093/nar/21.16.3623, 309856, 8367277.
32. Takeda S, Ichii S, Nakamura Y. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Hum Mutat 1993, 2:112-117. 10.1002/humu.1380020209, 8318987.
33. Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, Chen JS, Changchien CR, Hsieh LL. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 2004, 210:101-109. 10.1016/j.canlet.2004.01.006, 15172127.
34. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003, 21:271-276. 10.1002/humu.10175, 12619112.
35. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005, 23:5635-43. 10.1200/JCO.2005.04.096, 16110022.
36. Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, Yeh KH, Wang SM, Chang KJ. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 2002, 97:451-457. 10.1002/ijc.1637, 11802206.
37. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998, 58:1149-1158.
38. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N, . TP53-CRC Collaborative Study Group The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005, 23:7518-7528. 10.1200/JCO.2005.00.471, 16172461.
39. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999, 104:263-269. 10.1172/JCI6863, 408422, 10430607.
40. Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J, Lynch M, Johnston PG. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 2004, 10:3562-3571. 10.1158/1078-0432.CCR-03-0532, 15161716.